CLOSED
GET A PIECE OF LIGHTSENSE TECHNOLOGY
Public Health Detection Simplified
Show more
$180,362.27 Raised
TEAM
Terje Skotheim, Ph.D. • CHIEF EXECUTIVE OFFICER
Read More
Bruce Berkoff • CHIEF MARKETING OFFICER
Read More
Wade Poteet, Ph.D. • CHIEF TECHNOLOGY OFFICER
Read More
Reasons to Invest
- We provide unique solutions to intractable problems in public health.
- Our unique EPS technology is applicable to many important and growing markets.
- Lightsense has a strong and experienced management team with innovative differentiated products powering future SaaS and disposable revenue pathways.
OVERVIEW
At Lightsense, we’re breaking new ground in public health
That’s because we are translating expensive, tabletop spectrometer instrumentation into miniaturized, handheld platforms - all with AI/ML powered optical detection technology that can serve a wide range of analytical applications.
Our focus is on utilizing this new class of tools to help solve some major problems in public health - such as detecting fentanyl and other illicit drugs in the opioid epidemic, detecting viral pathogens in the COVID-19 pandemic, as well as detecting bacterial pathogens in the food safety field.
We are a diverse and experienced group of successful scientists, engineers, and entrepreneurs focused on using modern optics techniques (especially miniaturized spectroscopy), advances in sensors and machine learning to attack problems related to public health in new, insightful ways.
THE PROBLEM
Public Health is facing some critical problems
In all the critical areas of public health - the common thread is that detection and testing solutions need to be faster, less expensive and more accurate.
THE SOLUTION
Meet the Multispectral Point-of-Need Analyzers
Lightsense has developed a multi-spectral technology platform, the patented “Enhanced Photodetection Spectroscopy” (EPS) , a radical new spectroscopy architecture, for chemical, molecular and pathogen identification.
Our devices can address critical analytical and detection problems in multiple areas of public health - like rapid detection of illicit drugs, rapid screening for viral/bacterial pathogens, and monitoring bacterial pathogens in various parts of the food supply chain.
When it comes to the science: Spectroscopy uses light of many wavelengths to analyze objects or chemical compounds. This light energy interrogates the molecule of interest and produces a spectral response - creating what scientists call a “spectral fingerprint.” This fingerprint contains large amounts of data, and with our multispectral approach, data fusion and analysis, we can increase sensitivity. AI/ML can be used to detect known patterns and monitor samples, like in the three mentioned areas of public health, above, where we are creating solutions and partnerships.
Machine Learning is a critical feature in our technology. It not only uses algorithms to detect patterns otherwise not visible and predict outcomes, EPS spectra contain large amounts of data which are aggregated in Cloud databases, allowing monetizing them as a new subscription service.
Our business model includes both hardware and SaaS components. What makes us unique is a radical new and patented spectroscopy that integrates three or more individual spectroscopies with data fusion and machine learning analytics. Our miniaturization technology allows the construction of integrated small and handheld instruments.
Our IP can also be licensed along with products in specific domain applications. Unique solutions can be crafted for individual partners and customers justifying licensing agreements and related higher margins.
We project our various hardware platforms to cost between $5K and $20K, and we believe we can outperform more expensive competing products, both in performance and in simplicity and ease of use. We project additional revenue from software (SaaS subscriptions) and for certain applications, disposable sample holders.
THE MARKET
Applications in a Multitude of Industries
Our applications and technology will find applications beyond traditional areas of Public Health. We anticipate that our devices will address critical analytical and detection problems in a wide range of large vertical markets.
Here’s the Total Addressable Markets (TAMS) from our initial focus markets.
Lightsense miniaturized handheld spectrometers can be used in a variety of analysis applications with performance comparable to that of laboratory instruments, but at a dramatically lower cost, and ease of use.
Our handheld spectrometers, both current products and instruments under development, are lightweight, easy to use, accurate, faster, and less expensive than competing technologies. We believe our technology will reach a multitude of industries.
Our Traction
Completed first raise, and accelerating with a second
We completed our first seed “A1” raise with SeedInvest, and will accelerate our developments with a second “A2” seed round now.
Among our recent accomplishments, we received a Food and Beverage Magazine Award for the top 10 food safety solutions providers (Source).
The basis for the Lightsense technology portfolio has been developed by a seasoned and accomplished team over many years. Collectively, we’ve been granted over 150 patents in our careers, on a wide range of technologies.
Currently, the Lightsense patent portfolio lineup includes:
- 7 issued or allowed patents on miniaturized spectrometers and EPS multi-spectral designs, including both Lightsense owned and exclusively licensed
- 4 patent applications
- Multiple patent applications in preparation
WHY INVEST
Providing more and sensitive data for machine learning
By focusing on new techniques for sample preparation and data analysis, as well as advances in sensors and machine learning - we expect to enable new solutions in areas of public health with very high sensitivity and easy-to-use products that are efficient and lower cost.
Success for us looks like ..
- Growing revenue and margin in our targeted areas, along with increased government contracts and awards to further our scientific foundations
- Having robust and profitable partnerships in 3-4 market segments that utilize our technologies in different ways
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
ABOUT
HEADQUARTERS
7080 N CATHEDRAL ROCK PL
Tucson, AZ 85718
WEBSITE
View Site
TERMS
Overview
PRICE PER SHARE
DEADLINE
Aug. 1, 2025 at 5:49 AM UTC
VALUATION
Breakdown
MIN INVESTMENT
MAX INVESTMENT
OFFERING TYPE
Maximum Number of Shares Offered subject to adjustment for bonus shares
ALL UPDATES
10.11.22
Final Hours Left to Invest!
Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, 11:59 pm, in less than 13 hours
Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!
Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:
10.10.22
Severn Safety Supply and Lightsense Technology team up for 2022’s International Association of Chiefs of Police (IACP) Conference being held in Dallas, Texas
October 10, 2022 – Tucson, AZ – Lightsense Technology, a pioneer of multi-spectroscopic solutions to address large problems in public health — from the opioid crisis to the pandemic, food safety and quality assurance in various supply chains — and Severn Safety Supply, a trusted supplier to Law Enforcement Organizations (LEOs) across the USA, are attending the IACP conference being held in Dallas, Texas, October 15th-18th. The companies have formed a strategic partnership to help bring the newly launched DrugDetect-F1 to more markets in specific areas of North America.
“We at Severn Safety Supply are very excited to be a part of this conference and to have the opportunity to meet with leaders in law enforcement from around the globe! We are looking forward to the opportunity to demonstrate the highly effective and technologically advanced DrugDetect-F1 product to these leaders. We believe the DrugDetect-F1 will significantly increase safety for their officers by minimizing the insidious danger posed by fentanyl and methamphetamine exposure. DrugDetech-F1’s detection technology marks an important transition to a more safe and effective drug detection method. The technology behind DrugDetect-F1’s contactless, ‘point and click’ method of testing is truly remarkable. Also exciting is the fact that these tests can be completed quickly, safely and efficiently, even when the product is contained in thin transparent packaging,” Commented Jeff Hall, President of Severn Safety Supply.
“We are thrilled to partner with the experienced Severn Safety team. This show will help us both gain exposure in the handheld detector market while reaching more law enforcement organizations with our unique new tools to help with our country’s growing fentanyl problem,” remarked Bruce Berkoff, CMO of Lightsense Technology. “The DrugDetect-F1 serves as compelling evidence of the power of our new spectroscopic detection technologies, which should make law officers safer and more efficient, while helping to save lives and money.
About Lightsense Technology
Lightsense has developed groundbreaking multi-spectral technology platforms, such as the patented “Enhanced Photodetection Spectroscopy” (EPS), a radical new spectroscopy architecture, for chemical, molecular and pathogen identification. Their advanced high-sensitivity mini-spectrometer designs also enable new lightweight and inexpensive handheld devices to address large vertical markets in “public health”, such as detection of illicit drugs, rapid screening for viral/bacterial pathogens, and monitoring bacterial pathogens in the food supply chain. All products are Designed, Made, & Calibrated in the USA
INVEST in a better future for all, see our new campaign page for our SEED round with StartEngine, at, https://www.startengine.com/lightsense-technology
10.10.22
IACP Trade Show Banners have arrived! Invest Now in Lightsense Technology!
We are excited to share with you one of our banners for our upcoming demo at the IACP trade show happening October 16-18 in Dallas Texas. With a focus on our recent launch of the DrugDetct-F1 (handheld point-of-use fentanyl detector). This show will be foundational for us in generating sales with many police and police agencies from around the US and the world and creating shareholder value. Please join us on our journey to Public Health Detection Simplified! Only 5 days left to invest.
10.09.22
2 Days Left to Invest!
Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 2 days away.
Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!
Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:
10.08.22
3 Days Left to Invest!
Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 3 days away.
Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!
Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:
10.07.22
4 Days Left to Invest!
Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 4 days away.
Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!
Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:
10.06.22
Lightsense Technology Announces New Manufacturing Partnership To Help with Climate Change and Grow Revenue
Lightsense Technology, a leading provider of multi-spectroscopic solutions, is announcing a new manufacturing partnership with a large international industrial company involved in making factory equipment for the high-tech global industry.
This partnership will allow Lightsense know-how and IP to be used to manufacture new tools to aid in factory production, helping to optimize production parameters as well as reduce greenhouse gas emissions and make more efficient use of inputs to generate more sustainable and profitable outputs. Additional details will be announced at a later date.
With this new partnership, Lightsense will be able to increase its revenue base and production capacity and continue its mission of improving public health, which now includes battling climate change.
Lightsense will be able to provide even more innovative solutions to the most pressing issues in public health facing our world today.
Invest now before our round closes in 7 days.
10.06.22
5 Days Left to Invest!
Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 5 days away.
Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!
Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:
10.05.22
6 Days Left to Invest!
Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 6 days away.
Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!
Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:
10.04.22
Lightsense Technology's Current Offering is Closing in Just 7 Days. Act Now!
Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 7 days away.
Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!
Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:
REWARDS
JOIN THE DISCUSSION
0/2500
Peter Koning
3 years ago
No reply to my question from 7 days ago. I'm out.
1
0
Peter Koning
3 years ago
Why is the focus on the drug (e.g. fentanyl) detection primarily on law enforcement. There are over 10,000 deaths in our province since 2016, due to this crisis. I have no issue with detection for enforcement, but interested in your thoughts on the market in detection related to saving lives?
Show more
1
0
Robert Danese
3 years ago
Very good content guys. Looking forward to the webinar.
0
0
Thawirat Chotirawi
3 years ago
Definitely interested in investing and hear more about your technology.
1
0
Shari Brandt
3 years ago
A month ago, John H reported being unable to invest in Lightsense because of a StartEngine bug on investing. I reported the same 3 days ago. StartEngine is taking a cut of Lightsense' startup funding but is not holding up on its end of the bargain. Start Engine needs to FIX THIS and then extend the time for Lightsense' raise and also work to promote it since it has impeded Lightsense' progress. BTW, StartEngine sent me a link to submit an investment and it doesn't work either. I strongly suggest Lightsense raise this issue with Start Engine also.
Show more
1
0
Shari Brandt
3 years ago
I'm interested in investing, but Start Engine's "Invest Now" link for this security isn't working--and hasn't for a few days now. I've notified Start Engine but have not received a response and the issue has not been corrected.
Show more
1
0
Hon Fai Choi
3 years ago
Hello, would it be possible to give your point of view on potential competitors and how your products relate to theirs? It is not mentioned in the pitch deck. Multi-purpose handheld spectrometers are already available on the market, and the ones you have developed seem to only target very specific compounds. What would be the edge that you have over your competitors? Thanks.
Show more
1
0
Jon Sims
3 years ago
What independent testing has been done on the accuracy of your products, and what were the results? Thanks.
Show more
1
0
John Hwung
3 years ago
Hi Lightsense Team, You may want to contact StartEngine management right now! I am trying to invest in your company, but I can't because there is a bug: When I clicked the "INVEST NOW" button, I get directed to a page to open a new account. The thing is: I have been investing on StartEngine Platform for the past 3 years. -John Hwung
Show more
2
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
StartEngine makes it easy to invest using your retirement funds. You can open a self-directed IRA account through Equity Trust, a trusted provider fully integrated with our platform. This integration allows for a fast, secure, and seamless investing experience, and includes a special offer on annual feesexclusively for StartEngine investors.
Already have a self-directed IRA with another provider? You can still invest on StartEngine, but please note that the process will be manual and may take longer to complete.
To get started, simply visit our IRA page for more information and step-by-step instructions.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
PINNED BY STARTUP
David Slegh
3 years ago
Thank you for the great webinar. I am a returning investor and have done my homework on the Lightsense offering and its eligibility for the majority of the QSBS requirements. Similar question to what I asked during the funding round on another funding platform. I am wondering if Lightsense can provide confirmation that the company has less than $50 million in aggregate gross assets immediately after the StartEngine offering closes and that at least 80% of the company's assets are expected to be used in the active conduct of business (essentially just confirming that you are not expecting to be an investment company whose primary line of business in buying ownership in other companies). Is this something that would be possible to obtain?
Show more
2
0